{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:05:04Z","timestamp":1792137904515,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006662","name":"National Institute for Health Research (NIHR)","doi-asserted-by":"publisher","award":["PDF-2012-05-245"],"award-info":[{"award-number":["PDF-2012-05-245"]}],"id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jinf.2014.07.002","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T03:45:19Z","timestamp":1405655119000},"page":"470-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero\u00ae)"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-2476","authenticated-orcid":false,"given":"Shamez N.","family":"Ladhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Cordery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2014.07.002_bib1","series-title":"Guidance for public health management of meningococcal disease in the UK","author":"Health Protection Agency","year":"2011"},{"issue":"5","key":"10.1016\/j.jinf.2014.07.002_bib2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jama.1997.03540290041030","article-title":"School-based clusters of meningococcal disease in the United States. Descriptive epidemiology and a case-control analysis","volume":"277","author":"Zangwill","year":"1997","journal-title":"JAMA"},{"issue":"7452","key":"10.1016\/j.jinf.2014.07.002_bib3","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/bmj.328.7452.1339","article-title":"Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review","volume":"328","author":"Purcell","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2014.07.002_bib4","series-title":"Surveillance and prevention of meningococcal disease in Denmark 1980\u201396","author":"Samuelsson","year":"1999"},{"issue":"11","key":"10.1016\/j.jinf.2014.07.002_bib5","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1017\/S0950268808000770","article-title":"Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: a systematic review","volume":"136","author":"Hoek","year":"2008","journal-title":"Epidemiol Infect"},{"issue":"7","key":"10.1016\/j.jinf.2014.07.002_bib6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.jinf.2014.07.002_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40265-013-0155-7","article-title":"A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program","volume":"74","author":"O'Ryan","year":"2014","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.jinf.2014.07.002_bib8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/hv.4513","article-title":"Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them","volume":"3","author":"Holst","year":"2007","journal-title":"Hum Vaccin"},{"issue":"4","key":"10.1016\/j.jinf.2014.07.002_bib9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/INF.0b013e31827b0d24","article-title":"A randomized, controlled, phase 1\/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents","volume":"32","author":"Nissen","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jinf.2014.07.002_bib10","series-title":"Update on the outcome of consultation about use of Bexsero\u00ae meningococcal B vaccine in the UK","author":"Joint Committee on Vaccination and Immunisation (JCVI)","year":"2013"},{"issue":"10","key":"10.1016\/j.jinf.2014.07.002_bib11","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1128\/CVI.00202-12","article-title":"Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines","volume":"19","author":"Plikaytis","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"45","key":"10.1016\/j.jinf.2014.07.002_bib12","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jinf.2014.07.002_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/adc.2003.031369","article-title":"Clusters of meningococcal disease in school and preschool settings in England and Wales: what is the risk?","volume":"89","author":"Davison","year":"2004","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.jinf.2014.07.002_bib14","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"43","key":"10.1016\/j.jinf.2014.07.002_bib15","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.jinf.2014.07.002_bib16","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","article-title":"Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines","volume":"30","author":"Ladhani","year":"2012","journal-title":"Vaccine"},{"issue":"9816","key":"10.1016\/j.jinf.2014.07.002_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jinf.2014.07.002_bib18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jinf.2014.07.002_bib19","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jinf.2014.07.002_bib20","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.vaccine.2010.11.064","article-title":"Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1","volume":"29","author":"Brunelli","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.jinf.2014.07.002_bib21","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"23","key":"10.1016\/j.jinf.2014.07.002_bib22","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jinf.2014.07.002_bib23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"9854","key":"10.1016\/j.jinf.2014.07.002_bib24","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(12)61187-8","article-title":"Effect of vaccines on bacterial meningitis worldwide","volume":"380","author":"McIntyre","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2014.07.002_bib25","series-title":"Impact of Quadrivalent Conjugate (MenACWY- CRM) and Serogroup B (4CMenB) Meningococcal Vaccines on Meningococcal Carriage in English University Students [ABSTRACT]","first-page":"05","author":"Read","year":"2013"},{"issue":"4","key":"10.1016\/j.jinf.2014.07.002_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(13)70332-3","article-title":"Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004-11: an observational study","volume":"14","author":"Okike","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2014.07.002_bib27","first-page":"CD004785","article-title":"Antibiotics for preventing meningococcal infections","volume":"4","author":"Fraser","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"6673","key":"10.1016\/j.jinf.2014.07.002_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/bmj.298.6673.569","article-title":"Does eradication of meningococcal carriage in household contacts prevent secondary cases of meningococcal disease?","volume":"298","author":"Stuart","year":"1989","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jinf.2014.07.002_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/eri.12.161","article-title":"Genetic susceptibility to meningococcal infection","volume":"11","author":"Dale","year":"2013","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445314001984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445314001984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:20:05Z","timestamp":1759008005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445314001984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0163445314001984"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2014.07.002","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero\u00ae)","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2014.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}